Medistem, Inc. engages in the development and commercialization of adult stem cell therapies in the United States. The company is developing endometrial regenerative cell (ERC), a universal donor stem cell product that promotes new blood vessel formation (angiogenesis), reduce inflammation, regulate immune system function, and augment tissue repair and healing. It is developing ERCs to treat a range of diseases, including ischemic conditions, cardiovascular and neurological diseases, kidney failure, liver failure, pulmonary diseases, and orphan disease indications, as well as autoimmune diseases, such as type 1 diabetes. The company was formerly known as Medistem Laboratories, Inc. and changed its name to Medistem, Inc. in August 2008. Medistem, Inc. is headquartered in San Diego, California.
February 7, 2014
A bipolar sector dents weekly losses
February 6, 2014
No news, mixed signals as equities regain footing
February 5, 2014
Sell-offs coming on lower volumes
February 4, 2014
Is being oversold, a “chronic “condition
February 4, 2014
High equity market sensitivity
February 3, 2014
RegMed better reprise as volumes “don’t lie”
February 3, 2014
Curdling sentiment and conviction
January 31, 2014
It’s a jungle out there
January 29, 2014
The risk curve gauges even higher
January 29, 2014
It’s only over, when fat pricing gets to a bottom
35 companies, 1 interpreter!
Insight, foresight and recommendation
SOLD to Intrexon (NYSE: XON). MEDS stockholders will receive $0.27 in cash and $1.08 worth of XON’s common stock, based on the 20-day volume-weighted average price of the stock immediately prior to closing. MEDS platform has been saved; having NOT being able to raise capital – having been on a “thin” string for a while - it was the only “play or option” left!
goneMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors